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ResistanceCancer cells exhibit an endogenous constitutive oxidative stress higher than that of normal cells, which renders
tumours vulnerable to further reactive oxygen species (ROS) production. Mitochondrial uncoupling protein 2
(UCP2) canmitigate oxidative stress by increasing the inﬂux of protons into themitochondrialmatrix and reduc-
ing electron leakage and mitochondrial superoxide generation. Here, we demonstrate that chemical uncouplers
or UCP2 over-expression strongly decrease mitochondrial superoxide induction by the anticancer drug
gemcitabine (GEM) and protect cancer cells from GEM-induced apoptosis. Moreover, we show that GEM IC50
values well correlate with the endogenous level of UCP2 mRNA, suggesting a critical role for mitochondrial
uncoupling in GEM resistance. Interestingly, GEM treatment stimulates UCP2 mRNA expression suggesting
that mitochondrial uncoupling could have a role also in the acquired resistance to GEM. Conversely, UCP2 inhi-
bition by genipin or UCP2 mRNA silencing strongly enhances GEM-induced mitochondrial superoxide genera-
tion and apoptosis, synergistically inhibiting cancer cell proliferation. These events are signiﬁcantly reduced by
the addition of the radical scavenger N-acetyl-L-cysteine or MnSOD over-expression, demonstrating a critical
role of the oxidative stress. Normal primary ﬁbroblasts are much less sensitive to GEM/genipin combination.
Our results demonstrate for the ﬁrst time that UCP2 has a role in cancer cell resistance to GEM supporting the
development of an anti-cancer therapy based on UCP2 inhibition associated to GEM treatment.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Gemcitabine (2′,2′-diﬂuoro-2′-deoxycytidine; GEM) is a critical
component of therapeutic regimens in a broad range of malignancies,
including pancreas, lung and bladder carcinomas, and represents one
of the main options when combination therapy is employed. Despite
more than 20 years of clinical use of GEM, its comprehensive mecha-
nism of action on tumour cells is not fully elucidated. Currently,
cancer research is focused on the identiﬁcation of novel potential
targets of response, the regulation of which may improve GEM anti-
tumour activity.
Studies by our research group have recently demonstrated that
the induction of reactive oxygen species (ROS) is one of the mecha-
nisms of GEM antitumour action and that pancreatic adenocarcinoma
cell lines with lower basal levels of ROS are more resistant to GEM
compared to cells with higher ROS levels [1]. Compromised aerobic
metabolism, nutrient deprivation, and host immune responses are
among the main causes of the high ROS generation in cancer cells
[2–4]. Ensuring that ROS levels remain in the non-toxic range is aoduction Sciences, Section of
37134 Verona, Italy. Tel.: +39
adelli).
l rights reserved.continuous challenge for cancer cells, which invoke a suite of anti-
oxidative defense strategies.
Uncoupling proteins (UCPs) belong to the superfamily of mitochon-
drial anion transporters [5,6]. In mammals, ﬁve different UCP homo-
logues have been described, UCP 1–5, which have different levels of
identity and different tissue distribution [7]. Several studies have
shown that the antioxidant UCP2 is broadly over-expressed in cancer
cells [8,9]. Increased UCP2 expression, associated with hypomethylation
of its gene, was found in several hepatocellular cancer cell lines and
suggested a role for epigenetic modiﬁcations in cancer UCP2 over-
expression [8]. This feature may represent an adaptive mechanism
developed by tumours to maintain ROS homeostasis [7,10]. UCP2
prevents mitochondrial superoxide generation, a major cause of
the cellular oxidative damage [11], by increasing the proton ﬂow
into thematrix thus rendering the electron ﬂow through the respiratory
complexes more efﬁcient [12,13]. Indeed, even slight depolarisation of
the ΔΨm can diminish electron escape and reduce mitochondrial
superoxide production [14,15].
Recently, tumour xenografts of UCP2-overexpressing colon cancer
cells have been shown to be muchmore resistant to the topoisomerase I
inhibitor CPT-11 as compared to control cells [16]. Moreover, Mailloux et
al. demonstrated that the speciﬁc UCP2 inhibitor, genipin, was able to
sensitise drug-resistant leukemia cells to anthracyclin [17], suggesting
that UCP2 targeting may be a novel therapeutic strategy for cancer.
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UCP2 gene regulation in the cell resistance toGEMand the antitumoural
effect of GEM treatment associated to UCP2 inhibition. We used as cel-
lular models tumours clinically treated with GEM, i.e. pancreas ade-
nocarcinoma, non-small cell lung adenocarcinoma, and bladder
carcinoma, and primary ﬁbroblasts as normal control.
2. Materials and methods
2.1. Chemicals
Gemcitabine (2′,2′-diﬂuoro-2′-deoxycytidine; GEM) was provided
by Eli Lilly (Florence, Italy) andwas solubilised in sterile water. Genipin
(methyl-2-hydroxy-9-hydroxymethyl-3-oxabicyclonona-4,8-diene-5-
carboxylate) and TTNPB (5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-
naphthalenyl-1-propenyl benzoic acid) were obtained from Sigma
(Milan, Italy), solubilised in DMSO and stored at−80 °C until use. FCCP
(4-triﬂuoro-methoxy-phenyl-hydrazone) was obtained from Sigma
(Milan, Italy), solubilised in 95% ethanol and stored at−20 °C until use.
2.2. Cell culture
Pancreatic adenocarcinoma cell lines PaCa44, PaCa3, Panc1,
CFPAC1, T3M4, andMiaPaCa2were grown in RPMI 1640 supplemented
with 2 mM glutamine, 10% FBS, and 50 μg/ml gentamicin sulfate
(BioWhittaker, Lonza, Bergamo, Italy). Non-small cell lung adenocarci-
noma cell lineA549, bladder carcinomaRT112 cell line (kindly provided
by Dr. Paco Francisco Real; Centro Nacional de Investigaciones
Oncológicas;Madrid, Spain), and normal primary ﬁbroblasts (PromoCell,
PBI, Milan, Italy) were grown in DMEM supplemented with 2 mM
glutamine, 10% FBS, and 50 μg/ml gentamicin sulfate (BioWhittaker,
Lonza, Bergamo, Italy). All cell lines were incubated at 37 °C with 5%
CO2.
2.3. Cell proliferation assay
Cells were seeded in 96-well plates (5×103 cells/well), 24 h later
treated with the various compounds and further incubated for the indi-
cated times (see legends to ﬁgures). At the end of the treatments cells
were stained with a Crystal Violet solution (Sigma, Milan, Italy). The dye
was solubilised in PBS containing 1% SDS and measured photometrically
(A595nm) to determine cell growth.
2.4. Drug combination studies
Drug combination studies were performed using the concentration
ratio [GEM]:[genipin]=1:500, which was chosen on the basis of GEM
or genipin IC50 mean values. Taking into account the drug molar ratios,
the in vitro ranges of concentration used were 20 nM→2 μM for GEM
and 10 μM→1 mM for genipin. The Combination Index (CI) was calcu-
lated by the Chou–Talalay equation, which takes into account both the
potency (IC50) and the shape of the dose–effect curve [18,19], taking ad-
vantage of the CalcuSyn software (Biosoft, Cambridge, UK). The general
equation for the classic isobologram is given by CI=(D)1/(Dx)1+(D)2/
(Dx)2+[(D)1·(D)2]/[(Dx)1·(Dx)2], where (Dx)1 and (Dx)2 in the de-
nominators are the doses (or concentrations) for D1 (drug 1) and D2
(drug 2) alone that gives x% growth inhibition, whereas (D)1 and (D)
2 in the numerators are the doses of drug 1 and drug 2 in combination
that also inhibit x% cell growth (i.e., isoeffective). CIb1, CI=1, or CI>1
generally indicate synergistic, additive, or antagonistic effect, respec-
tively. However, to obtain more compelling data, we decided to use a
cut off for CI of 0.7 (as suggested by manufacturer directions), identify-
ing a synergistic effect when CIs were smaller than 0.7. CI/effect curves
represent the CI versus the fraction (0→1) of cells killed by drug com-
binations. The synergism percentage was obtained analysing CI/effectcurve and measuring the CI values at each 0.05 fraction, i.e. 5% growth
inhibition, of the antiproliferative effect.
2.5. Measurement of mitochondrial superoxide production
The non-ﬂuorescent MitoSox Red probe (Molecular Probes,
Invitrogen, Milan, Italy) was used to evaluate mitochondrial O2•− pro-
duction. Brieﬂy, cells were seeded in 96-well plates (5×103 cells/well)
and, the day after, treated with the various compounds at the indicated
concentration for 16 h. At the end of the treatments, cells were incubat-
ed in culture medium with 0.5 μM MitoSox probe at 37 °C for 15 min.
Cells were washed with Hanks buffer (20 mM Hepes pH 7.2, 10 mM
glucose, 118 mM NaCl, 4.6 mM KCl, and 1 mM CaCl2) and ﬂuorescence
was measured by using a multimode plate reader (Ex 430 nm and Em
590 nm) (GENios Pro, Tecan, Milan, Italy). The probe is live-cell per-
meant and is rapidly and selectively targeted to the mitochondria
where it becomes ﬂuorescent after oxidation by O2•−. The usage of
430±35 nm of excitation wavelengths allowed us to selectively detect
mitochondrial O2•− strongly reducing the recognition of other oxidants
(e.g., ∙OH, ONOO.−) [20–22]. The values were normalised on cell prolif-
eration by Crystal Violet assay.
2.6. RNA extraction and qPCR
Total RNA was extracted from cells using a highly denaturing
guanidine-thiocyanate-containing buffer and RNeasy Mini spin columns
(Qiagen,Milan, Italy). The concentration of puriﬁedRNAwas determined
measuring the absorbance at 260 nmwith aNanoDrop 1000 spectropho-
tometer (Thermo Scientiﬁc, Milan, Italy). 1 μg of RNA was reverse tran-
scribed using SuperScript® VILO cDNA Synthesis Kit (Invitrogen, Milan,
Italy). Real time PCR analyses were performed with a QuantiTect SYBR
Green PCR kit (Qiagen, Milan, Italy) and a Rotor-Gene™ 6000 (Corbett
Research, Cambridge, UK) using the following primers: Hs_UCP2_1_SG
QuantiTect Primer Assay for the UCP2 gene and Hs_RRN18S_1_SG
QuantiTect Primer Assay (Qiagen, Milan, Italy) for 18S rRNA. The ampli-
ﬁcation conditions consisted in an initial step of 15 minutes at 95 °C to
activate HotStarTaq DNA polymerase and 45 cycles of denaturation at
94 °C for 15 seconds, annealing at 55 °C for 30 seconds, and extension
at 72 °C for 30 seconds.
2.7. Immunoblot analysis
Cells were harvested, washed in phosphate-buffered saline, and
re-suspended in 50 mM Tris–HCl pH 7.5, 150 mM NaCl, 1% Triton
X-100, 1 mMPMSF, and 1×protease inhibitor cocktail (RocheDiagnostic,
Monza, Italy). After three freeze/thaw cycles and incubation on ice for
15 min, the lysate was centrifuged at 14,000 ×g for 10 min at 4 °C and
the supernatant used for Western blot. Protein concentration was mea-
sured with the Bradford protein assay reagent (Pierce, Milan, Italy)
using bovine serum albumin as a standard. Protein extracts (15 μg/lane
for MnSOD or 35 μg/lane for PARP) were electrophoresed through a 12%
(MnSOD) or 7.5% (PARP) SDS-polyacrylamide gel and electro-blotted
onto PVDF membranes (Millipore, Milan, Italy). Membranes were then
incubated overnight at 4 °C with blocking solution [5% low-fat milk in
TBST (100 mM Tris pH 7.5, 0.9% NaCl, 0.1% Tween 20)] and probed for
1 h at room temperaturewith amousemonoclonal anti-MnSODantibody
(1:2000 in blocking solution; Abcam, Cambridge, UK) or a rabbit
monoclonal anti-PARP antibody (1:1000 in blocking solution; Cell
Signaling, Milan, Italy). Horseradish peroxidase conjugated anti-mouse
IgG (for MnSOD detection) or anti-rabbit IgG (for PARP detection)
(1:8000 in blocking solution; Upstate Biotechnology, Milan, Italy) were
used to detect speciﬁc proteins. Immunodetection was carried out using
chemiluminescent substrates (Amersham Pharmacia Biotech, Milan,
Italy) and recorded using a HyperﬁlmECL (Amersham Pharmacia
Biotech). Ponceau S dye was used as control loading.
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Cells were seeded in 96-well plates (5×103 cells/well) and, the
day after, treated with the various compounds at the indicated con-
centrations for 48 h. At the end of the treatment, cells were ﬁxed
with 2% paraformaldehyde in PBS at room temperature for 30 min,
then washed twice with PBS and stained with annexinV/FITC (Bender
MedSystem, Milan, Italy) in binding buffer (10 mM HEPES/NaOH pH
7.4, 140 mMNaOH, and 2.5 mMCaCl2) for 10 min at room temperature
in the dark. Finally, cells were washed with binding buffer solution and
ﬂuorescence was measured by using a multimode plate reader (Ex
485 nm and Em 535 nm) (GENios Pro, Tecan, Milan, Italy). The values
were normalised on cell proliferation by Crystal Violet assay.0
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§ †2.9. Transient transfection experiments
Exponentially growing cells were seeded at a density of 5×103 cells/
well in 96-well plates for proliferation assays and at 2.5×105 cells/plate
in 60 mm cell culture plates for protein extraction. Twenty-four hours
later, transfections were carried out with a pCR3.1 expression vector
containing the cDNA of human MnSOD (kindly provided by Dr. Akashi,
National Institute of Radiological Sciences, Chiba, Japan) using
TransIT-LT1 transfection reagent (Mirus, Tema Ricerca, Bologna, Italy)
according to manufacturer. Cells transfected with the empty pCR3.1
vector were used as a control and behaved as the untransfected cells
(data not shown). Cells were incubated for 24 h and then treated with
GEM/genipin for the indicated periods.
UCP2 over-expression experiments were performed using a pCMV
expression vector containing the human cDNA of UCP2 (OriGene
Technologies, Rockville, MD) using TransIT-LT1 transfection reagent
(Mirus, Tema Ricerca, Bologna, Italy). Cells transfected with the
empty pCMV vector were used as a negative control (mock). Cells
were incubated for 24 h and treated with GEM to evaluate the effect
of UCP2 over-expression on GEM-induced cell growth inhibition and
apoptosis.20
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§ †2.10. siRNA transfections and UCP2 silencing
Exponentially growing cells were seeded at a density of 5×103 cells/
well in 96-well plates for proliferation assays and at 2.5×105 cells/plate
in 60 mm cell culture plates for RNA extraction. Twenty-four hours
later, transfections were carried out with a speciﬁc small interfering
(si) (5′-GCUAAAGUCCGGUUACAGATT-3′) RNA targeting UCP2 mRNA
and a non-targeting (NT) siRNA (5′-CAGUCGCGUUUGCGACUGG-3′)
purchased by Ambion Life Technologies (Monza MB, Italy). Cells were
transfected with siRNAs at a ﬁnal concentration of 200 nM using Trans-
fectin for 72 h (Biorad, Milan, Italy).0
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Fig. 1. Effects of GEM on cell growth (A), apoptosis (B), and mitochondrial superoxide
production (C) in the absence or presence of FCCP, TTNPB, UCP2 over-expression or
empty vector (mock). Cells were seeded in 96-well plates, incubated overnight, and treated
with 1 μMGEM (48 h) alone or in the presence of 1 μMFCCP or 300 nM TTNPB for 48 h
(A and B) or 16 h (C). UCP2 over-expression was performed transfecting cells with
100 ng pCMV-UCP2 vector or pCMV empty vector using TransIT-LT1 transfection reagent
for 72 h (A and B). Cell proliferation was determined using the Crystal Violet colorimetric
assay; apoptosis was analysed using the annexin V binding assay;mitochondrial superoxide
production was determined using the MitoSox Red probe as described in Materials and
methods. Values are the means (±SD) of three independent experiments each performed
in triplicate. Statistical analysis: (*) Pb0.05 GEM+FCCP vs GEM; (§) Pb0.05 GEM+TTNPB
vs GEM; (†) Pb0.05 GEM+UCP2 o.e. vs GEM or GEM+mock.2.11. Caspase activity
Cells were seeded in 96-well plates (5×103 cells/well) and, the day
after, treated with the various compounds at the indicated concen-
trations for 48 h. At the end of the treatments, cells were incubated in
culture medium with the ﬂuorescent inhibitor/substrate of caspases
FLICA (FAM-DEVD-FMK) (Molecular Probes, Invitrogen, Milan, Italy)
for 60 min at 37 °C. FLICA reagent contains a carboxyﬂuorescein group
(FAM) and a ﬂuoromethyl ketone (FMK)moiety, which can react cova-
lently with a cysteine residue. The recognition sequence aspartic acid–
glutamic acid–valine–aspartic acid (DEVD) is speciﬁc for caspase-3
and ‐7. Cells were washed twice with wash buffer and ﬂuorescence
was measured by using a multimode plate reader (Ex 485 nm and Em
535 nm) (GENios Pro, Tecan, Milan, Italy). The values were normalised
on cell proliferation by Crystal Violet assay.2.12. Statistical analysis
ANOVA (post hoc Bonferroni) analysis was performed by GraphPad
Prism 5 software. P valueb0.05was indicated as statistically signiﬁcant.
3. Results
3.1. Mitochondrial uncoupling reduces GEM effect in cancer cells
To evaluate the impact of mitochondrial uncoupling on GEM effects,
we treated cells with GEM in the absence or presence of FCCP, a known
chemical uncoupler, TTNPB, a retinol compound able to activate UCP2
proton conductance [23,24], or UCP2 over-expression. Low concentra-
tions of FCCP or TTNPB signiﬁcantly protected cells from GEM-induced
cell growth inhibition (Fig. 1A) and apoptosis (Fig. 1B), and prevented
mitochondrial superoxide induction by GEM (Fig. 1C). In line with pub-
lished data, Supplementary Fig. 1A and B shows that while low concen-
trations of FCCP determined a modest proliferative and anti-apoptotic
effect, high concentrations were toxic to the cells. TTNPB treatment
was instead slightly effective on cell proliferation at the higher concen-
trations tested (Supplementary Fig. 1C). Consistently, cell growth inhi-
bition and apoptosis by GEM was signiﬁcantly reduced by UCP2 over-
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cytoﬂuorimetric analysis as representatively shown in Supplementary
Fig. 2A and ranged between 30% and 45% (Supplementary Fig. 2B).
The fold induction of UCP2 mRNA after pCMV-UCP2 or empty vector
transfectionwas analysed using qRT-PCR and reported in Supplementary
Fig. 3A.
To further investigate the involvement of UCP2 in the cellular re-
sistance to GEM, we characterised a panel of six cell lines belonging
to the same tumour type (human pancreatic adenocarcinoma) for
UCP2 expression (Fig. 2A) and we found that the basal level of UCP2
mRNA well correlated with GEM IC50 values (Fig. 2B). Consistent with
the antioxidant role of UCP2, the constitutive endogenous amount of
mitochondrial superoxide inversely correlated with UCP2 mRNA level
(Fig. 2C). Altogether, these data indicate that UCP2-mediated mito-
chondrial uncoupling has a critical role in intrinsic cancer resistance
to GEM. Additionally, inasmuch as GEM was able to induce UCP2B
r = 0.923
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Fig. 2. Analysis of the constitutive expression of UCP2 mRNA in a panel of six pancreatic
adenocarcinoma cell lines (A). Gene expression analysis of UCP2 was normalised to 18S
rRNA and values are reported as arbitrary units (a.u.) calculated assigning the value of
1 to the pancreatic cancer cell line (T3M4) harbouring the lowest UCP2 mRNA level.
Values are the means (±SD) of three independent experiments each performed in
triplicate. Correlation between the constitutive expression of UCP2 mRNA and the
GEM IC50 at 48 h (B) or the mitochondrial superoxide basal level (C). The MitoSox
Red ﬂuorescence intensity, corresponding to the level of mitochondrial superoxide
production, is reported as relative mean ﬂuorescence values (RMF). RMF is the ratio be-
tween ﬂuorescence intensity of MitoSox treated versus untreated (autoﬂuorescence)
cells.mRNA expression in all cell lines tested (Fig. 3), we suggest a role
of UCP2 induction also in the acquired cancer resistance to GEM.
3.2. GEM treatment and UCP2 inhibition synergistically inhibit cancer
cell proliferation
The antiproliferative effect of GEM in combination with genipin, a
highly selective inhibitor of UCP2 [25], or with UCP2 siRNA was exam-
ined on three cancer cell lines (A549, PaCa44, and RT112) and normal
ﬁbroblasts. Both UCP2 inhibition by genipin or UCP2 silencing by
siRNA in combination with GEM signiﬁcantly increased cell growth in-
hibition as compared to single treatments in all cancer cell lines, but
in ﬁbroblasts (Fig. 4A and B). The efﬁciency of UCP2 silencing by
siRNA targeting UCP2mRNA or non-targeting (NT) siRNAwas analysed
using qRT-PCR and reported in Supplementary Fig. 3B.
To evaluate whether GEM in combination with the UCP2 inhibitor
genipin determined a synergistic effect, we analysed cell growth inhibi-
tion curves by using the dedicated software CalcuSyn (seeMaterials and
methods). Dose-dependent analyses performed at 48 h with different
concentrations of GEM and/or genipin revealed that the combined
setting induced a relevant percentage of antiproliferative synergism
in cancer cells (53%, 62.5%, and 85.5%, for A549, PaCa44, and RT112
cell lines, respectively), which was instead modest (7.5%) in normal
ﬁbroblasts (Fig. 4C). Fig. 4D shows the isobologram curves of the com-
bination index (CI) values versus the fraction (0→1) of cells killed by
drug combination. The CI50 values were 0.43, 0.56, and 0.66 for A549,
PaCa44, and RT112 cells, respectively, while it was 0.89 for normal
ﬁbroblasts (Table 1). Notably, a 2.3- up to 56.98-fold reduction in the
IC50 of GEM and a 1.5- up to 711-fold reduction in the IC50 of genipin
(DRI50) were observed in combination settings compared to single
treatments (Table 1).
To analyse the trend of the inhibitory effect over the time, we per-
formed a time-dependent analysis of the antiproliferative activity
following a 24 h single-step treatment with low concentrations of
GEM and/or genipin. Fig. 4E shows that, at the sixth day, the combined
treatment was able to signiﬁcantly reduce proliferation of cancer cells,
but that of ﬁbroblasts, as compared to single treatments, with a growth
ratio reduction versus untreated cells of 58%, 49.2%, and 53.8% for A549,
PaCa44, and RT112 cell lines, respectively.
3.3. GEM treatment and UCP2 inhibition strongly induce mitochondrial
superoxide production in cancer cells
In consideration of the described capability of UCP2 inhibition [7]
or GEM treatment [26] to stimulate mitochondrial superoxide produc-
tion in cancer cells, we investigated whether the association of GEM
with genipin or UCP2 siRNA could enhance mitochondrial superoxide0
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methods. The ﬁgure shows the fractional effects versus the different CIs. The fractional effect is the % of cell growth inhibition given by each combination of the two drugs
maintaining the same molar ratio (1:500) and increasing drug concentrations. This value is represented on the X axis of the curve. CI values obtained by the same combinations
are reported on the Y axis. CIs below 0.7 indicate synergistic conditions. (E) Cells were seeded in 96-well plates and incubated overnight. The compounds were added at low con-
centrations for 24 h: 100 nM GEM and/or 50 μM genipin. The values on the X axis correspond to the days after the beginning of the treatments at which cell growth was analysed.
The growth ratio on the Y axis was obtained by dividing the absorbance of untreated or treated cell lines by the mean absorbance of each cell line measured at time 0 and corre-
sponds to the folds of cell proliferation increase from the beginning of cell treatments. The bar corresponds to the time period relative to the presence of GEM and/or genipin in
culture medium (24 h) after which cells were maintained in drug-free medium. Values are the means of triplicate samples from three independent experiments. Statistical analysis:
(§) Pb0.05 GEM+genipin vs GEM or genipin.
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mined an induction of mitochondrial superoxide much higher than
that induced by single compounds. Notably, inﬁbroblasts, the intensity of
mitochondrial superoxide induction was very low and its enhancementby drug combination did not occur. Similar results were obtained after
UCP2 silencing in combination with GEM treatment (Fig. 5B). As
expected, mitochondrial superoxide induction by GEM+genipin com-
bined treatment was signiﬁcantly reduced by the radical scavenger
Table 1
Combination Index (CI) and Dose Reduction Index (DRI) values for GEM and genipin
combination.
CELL LINES CI50 DRI50 r
Fibroblasts 0.89 GEM: 4.27 0.92
genipin: 1.52
A549 0.43 GEM: 2.33 0.86
genipin: 711.53
PaCa44 0.56 GEM: 8.93 0.98
genipin: 2.25
RT112 0.66 GEM: 56.98 0.94
genipin: 1.55
CI50 was calculated for 50% cell growth inhibition in the combined treatment by
isobologram analyses performed with the CalcuSyn software. DRI50 represents the fold
of dose reduction to obtain 50% cell growth inhibition in combination setting a
compared to each drug alone.
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Fig. 5. Effects of GEM and UCP2 inhibition on mitochondrial superoxide production
(A) Cells were seeded in 96-well plates, incubated overnight, and treated with 1 μM
GEM and/or 500 μM genipin for 16 h. The ﬂuorescence intensity of the MitoSox Red
probe, corresponding to the level of mitochondrial superoxide production, was measured
by using a multimode plate reader, as described in Materials and methods. Values are the
means (±SD) of three independent experiments each performed in triplicate. Statistica
analysis: (§) Pb0.05 GEM+genipin vs GEM or genipin. (B) Cells were seeded in 96-wel
plates, incubated overnight, and treated with 200 nM UCP2 or NT siRNAs for 72 h and
or 1 μM GEM for the last 16 h. The ﬂuorescence intensity of the MitoSox Red probe
corresponding to the level of mitochondrial superoxide production, was measured by
using a multimode plate reader, as described in Materials and methods. Values are the
means (±SD) of three independent experiments each performed in triplicate. Statistica
analysis: (§) Pb0.05 GEM+UCP2 siRNA vs GEM or NT siRNA+GEM or UCP2 siRNA. (C
Cells were seeded in 96-well plates, incubated overnight, and treated with 1 μM GEM
and/or 500 μM genipin for 16 h, in the absence or presence of 10 mM NAC or MnSOD
over-expression (o.e.). Values are the means (±SD) of three independent experiment
each performed in triplicate. Statistical analysis: (#) Pb0.05 GEM+genipin+NAC
vs GEM+genipin; (*) Pb0.05 GEM+genipin+MnSOD o.e. vs GEM+genipin o
GEM+genipin+mock.
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rN-acetyl-L-cysteine (NAC) or by MnSOD overexpression (Fig. 5C). The
relative intensity of MnSOD before and after transfection with MnSOD
expression vector or empty vector was analysed and shown in Supple-
mentary Fig. 4A and B.
3.4. GEM treatment and UCP2 inhibition strongly induce ROS-mediated
apoptosis in cancer cells
Fluorescence analysis using annexinV-FITC assay shows that in
cancer cells both GEM+genipin and GEM+UCP2 siRNA signiﬁcantly
increased apoptosis induced by single treatments (Fig. 6A and B). In
normal ﬁbroblasts, apoptosis induction by single treatments was
lower than in cancer cells and was not enhanced by the combined
treatments. Fig. 6C shows that GEM/genipin-induced apoptosis and
cell growth inhibitionwere signiﬁcantly reduced by the radical scavenger
NAC or MnSOD over-expression. These data together with those
reported in Fig. 5 indicate that oxidative stress plays a critical role in
GEM+genipin antiproliferative effect.
To further analyse the apoptotic pathway, we evaluated caspase
activities and PARP cleavage after treatment with GEM and/or
genipin. In line with data reported in Fig. 6, caspase-3 and-7 activities
(Fig. 7A) and PARP cleavage (Fig. 7B) were higher in the combined
treatment as compared to single settings. Notably, both these events
were much less intense in normal ﬁbroblasts than in cancer cells.
Representative images of A549 cells stainedwith Hoechst to indentify
nuclei, FLICA to evaluate caspase-3 and ‐7 activities, or propidium iodide
to analyse nuclear membrane damage were reported in Supplementary
Fig. 5. In agreement with the previous data reporting the involvement
of massive apoptotic cell death, GEM+genipin combination rendered
cells muchmore positive to FLICA and propidium iodide staining as com-
pared to single treatments.
4. Discussion
The pyrimidine nucleoside analog GEM is one of the most safe and
employed drugs against a variety of solid tumours. Our research group
had previously demonstrated that oxidative stress plays a role in
pancreatic adenocarcinoma cell growth inhibition by GEM [1,26,27].
However, the clinical efﬁciency of GEM treatment is seriously impaired
by tumour-relatedmechanisms of cell resistance [28–30]. In the present
study, we have elucidated for the ﬁrst time the role of UCP2-mediated
mitochondrial uncoupling in cancer cell response to GEM. The cellular
models chosen (pancreatic adenocarcinoma, non-small cell lung adeno-
carcinoma, and bladder carcinoma) constitute tumour types whose
chemotherapeutic standard protocol is planned on GEM. We demon-
strate that the response of cancer cells to GEM is signiﬁcantly reduced
by the mitochondrial uncoupling inducers FCCP or TTNPB, or by UCP2
over-expression; on the contrary, it is strongly enhanced following
UCP2 silencing by siRNA or UCP2 inhibition by genipin, a highly selec-
tive inhibitor of UCP2-mediated proton leakage [25], via an oxidative
stress-dependent mechanism. In a panel of six pancreatic adenocarci-
noma cell lines, we report that increasing expression levels of UCP2
mRNA correlate directly with the GEM IC50 values and inversely
with the constitutive level of endogenous mitochondrial superoxide.
Altogether, these data and the observation that the UCP2 gene can be
induced byGEMdemonstrate that the antioxidant effect of themitochon-
drial uncoupling by UCP2 plays a critical role in cancer cell resistance to
GEM.
Besides UCP2 activation by superoxide ions and lipid peroxidation
products [11], it has been reported that the levels of UCP proteins in
tissues and cells is mainly regulated at the transcriptional level
[31,32]. Here, we show that UCP2 mRNA is induced by GEM, although
the identiﬁcation of the precise mechanisms of this induction needs
further investigation. Although GEM induces UCP2, the overall effect
of GEM in the redox status of the cell leans towards a pro-oxidant
outcome. Some authors have reported that GEM can generate ROS
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with 1 μM GEM and/or 500 μM genipin for 48 h. The FLICA ﬂuorescence intensity,
corresponding to the level of caspase-3 and ‐7 activities was measured by using a
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Fig. 6. Effects of GEM and UCP2 inhibition on apoptosis in the absence or presence of
NAC or MnSOD over-expression. (A) Cells were seeded in 96-well plates, incubated
overnight, and treated with 1 μM GEM and/or 500 μM genipin for 48 h. Apoptosis,
corresponding to the level of annexinV-FITC binding to the cells, was measured by
using a multimode plate reader, as described in Materials and methods. Values are
the means (±SD) of three independent experiments each performed in triplicate. Sta-
tistical analysis: (§) Pb0.05 GEM+genipin vs GEM or genipin. (B) Cells were seeded in
96-well plates, incubated overnight, and treated with 1 μM GEM for 48 h and/or 200
nM UCP2 siRNA or NT siRNA for 72 h. Apoptosis was analysed by the annexinV-FITC
binding assay. Values are the means (±SD) of three independent experiments each
performed in triplicate. Statistical analysis: (§) Pb0.05 GEM+UCP2 siRNA vs GEM or
NT siRNA+GEM or UCP2 siRNA. (C) Cells were seeded in 96-well plates, incubated
overnight, and treated with 1 μM GEM and/or 500 μM genipin for 48 h, in the absence
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binding or the percentage of cell growth relative to control (Crystal Violet assay)wasmea-
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with subsequent ceramide production [33,34], which directly affects
the mitochondrial electron transport chain [35]. Since mitochondrial
uncoupling can strongly decrease mitochondrial superoxide produc-
tion, we tried to further increase GEM-induced oxidative stress by
UCP2-mediated uncoupling inhibition. We report here that GEM is
able to induce UCP2 mRNA and mitochondrial superoxide, which in
turn is a main activator of UCP2 proton conductance [11], suggesting
that GEM acts as a mitochondrial uncoupling activator by at least two
different mechanisms. Genipin treatment or UCP2 siRNA strongly
synergise with GEM in cancer cell growth inhibition and apoptosis.
These events are mediated by ROS production as revealed by the strong
enhancement of mitochondrial superoxide production in the combined
treatment relative to single treatments and by the observation that mi-
tochondrial superoxide production and apoptosis induction show a
similar trend. Furthermore, we report that mitochondrial superoxideproduction, apoptosis and cell growth inhibition by GEM/genipin are,
at least partially, preventable by the addition of the radical scavenger
NAC or by over-expression of MnSOD, one of the main antioxidant en-
zymes located into mitochondria. The failure to totally inhibit GEM/
genipin-mediated oxidative stress could lie in the intrinsic cytotoxicity
of NAC when used at higher concentrations (data not shown) or in the
relatively low percentage of MnSOD transfected cells, ranging between
30% and 45% (see Supplementary Fig. 2). Interestingly, mitochondrial
superoxide production, apoptosis, and cell growth are only slightly
affected by GEM/genipin or GEM/UCP2 siRNA treatments in normal
primary ﬁbroblasts. These results can be explained by the observation
that cancer cells generally have an altered antioxidant defence system,
as compared to normal cells, a feature that represents a speciﬁc vulner-
ability of tumours [36] and can be selectively targeted by pro-oxidant
chemotherapeutics [4,26]. Although UCP2 inhibition by genipin increases
the sensitivity of cancer cells to GEM, our data on normal ﬁbroblasts indi-
cate that further efforts need to be addressed to identify low-toxic UCP2
inhibitors. Future in vivo experiments will be performed to deﬁnitely
support UCP2 inhibition as a successful anticancer strategy to enhance
the therapeutic efﬁciency of GEM.
5. Conclusions
In summary, we have demonstrated for the ﬁrst time that GEM in-
duces UCP2 mRNA and that mitochondrial uncoupling by UCP2 is a
mechanism of cancer cell resistance to GEM. We conclude that: i) the
basal level of mitochondrial superoxide is critical for the response to
GEM; ii) the basal level of mitochondrial superoxide is, at least in part,
determined by the expression level of UCP2; iii) UCP2 endogenous
expression could represent a potential predictive biomarker of cancer
resistance to GEM; iv) UCP2 can be considered an efﬁcient molecular
target to selectively inhibit cancer cell proliferation in combined
chemotherapeutic setting with GEM.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2012.06.007.
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